Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 14/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425413 | 0.90 | BDKRB1 (0.68) | BDKRB1ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL4420739 | 0.90 | BDKRB1 (0.68) | BDKRB1ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL6698072 | 0.88 | BDKRB1 (0.73) | BDKRB1ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL4432052 | 0.85 | ALDH1A1 (0.76) | BDKRB1ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL6406112 | 0.83 | BDKRB1 (0.67) | BDKRB1ALDH1A1POLB | |
| SCHEMBL4422565 | 0.83 | BDKRB1 (0.67) | BDKRB1ALDH1A1POLB | |
| SCHEMBL4431101 | 0.83 | BDKRB1 (0.67) | BDKRB1ALDH1A1POLB | |
| SCHEMBL6696538 | 0.82 | BDKRB1 (0.65) | BDKRB1ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL6697134 | 0.82 | BDKRB1 (0.65) | BDKRB1ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL6696537 | 0.82 | BDKRB1 (0.65) | BDKRB1ALDH1A1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635775-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635775-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040235849-A1 | Tetrahydroquinoxalines acting as bradykinin antagonists | BAYER HEALTHCARE AG (DE) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235849-A1 | Tetrahydroquinoxalines acting as bradykinin antagonists | BDKRB2, BDKRB1, LTB4R2 | BDKRB1 2/4885ALDH1A1 4292/4885POLB 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.